{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:10:48Z","timestamp":1790226648533,"version":"4.1.0"},"reference-count":170,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.esmoop.2024.103965","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T16:51:47Z","timestamp":1730393507000},"page":"103965","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Safety of solid oncology drugs in older patients: a narrative review"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8708-1664","authenticated-orcid":false,"given":"A.","family":"Rousseau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"G\u00e9raud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Geiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Farcet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-P.","family":"Spano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.-S.","family":"Hamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3064-7043","authenticated-orcid":false,"given":"P.","family":"Gougis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.esmoop.2024.103965_bib2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/annonc\/mdy551","article-title":"Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors","volume":"30","author":"Heinhuis","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2024.103965_bib3","article-title":"Systemic therapy in older patients with high-risk disease","volume":"43","author":"Brain","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103965_bib4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jgo.2017.08.012","article-title":"Are phase I trials safe for older patients?","volume":"9","author":"Baldini","year":"2018","journal-title":"J\u00a0Geriatr Oncol"},{"issue":"18","key":"10.1016\/j.esmoop.2024.103965_bib5","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"10.1016\/j.esmoop.2024.103965_bib6","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1200\/JCO.2004.02.175","article-title":"Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration","volume":"22","author":"Talarico","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2024.103965_bib7","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1200\/JCO.2003.12.044","article-title":"Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier?","volume":"21","author":"Yee","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2024.103965_bib8","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djp079","article-title":"Dose escalation methods in phase I cancer clinical trials","volume":"101","author":"Le Tourneau","year":"2009","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103965_bib9","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ijc.30417","article-title":"Outcomes of patients \u226565 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER","volume":"140","author":"Subbiah","year":"2017","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103965_bib10","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/01.mjt.0000183719.84390.4d","article-title":"Pharmacokinetic-pharmacodynamic crisis in the elderly","volume":"14","author":"ElDesoky","year":"2007","journal-title":"Am J Ther"},{"issue":"suppl 7","key":"10.1016\/j.esmoop.2024.103965_bib11","doi-asserted-by":"crossref","first-page":"vii36","DOI":"10.1093\/annonc\/mdt266","article-title":"Polypharmacy and the management of the older cancer patient","volume":"24","author":"Balducci","year":"2013","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103965_bib12","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jclinepi.2012.02.018","article-title":"Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes","volume":"65","author":"Gnjidic","year":"2012","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103965_bib13","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/cancers8010006","article-title":"Pharmacokinetics of selected anticancer drugs in elderly cancer patients: focus on breast cancer","volume":"8","author":"Crombag","year":"2016","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.esmoop.2024.103965_bib14","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1021\/mp400403s","article-title":"Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development","volume":"10","author":"Smelick","year":"2013","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103965_bib15","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3390\/curroncol28010076","article-title":"Proton pump inhibitors and oncologic treatment efficacy: a practical review of the literature for oncologists","volume":"28","author":"Uchiyama","year":"2021","journal-title":"Curr Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2024.103965_bib16","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/S1470-2045(13)70579-5","article-title":"Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective","volume":"15","author":"van Leeuwen","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2024.103965_bib17","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.critrevonc.2019.06.006","article-title":"Major pitfalls of protein kinase inhibitors prescription: a review of their clinical pharmacology for daily use","volume":"141","author":"Gougis","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"10.1016\/j.esmoop.2024.103965_bib18","article-title":"Association of systemic inflammation and sarcopenia with survival in nonmetastatic colorectal cancer: results from the C SCANS study","volume":"3","author":"Feliciano","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2024.103965_bib19","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.pharmthera.2018.12.003","article-title":"Body composition and sarcopenia: the next-generation of personalized oncology and pharmacology?","volume":"196","author":"Hilmi","year":"2019","journal-title":"Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103965_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0037563","article-title":"Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma","volume":"7","author":"Mir","year":"2012","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103965_bib21","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1093\/annonc\/mdx271","article-title":"Forcing the vicious circle: sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy","volume":"28","author":"Bozzetti","year":"2017","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103965_bib22","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3390\/diagnostics13020205","article-title":"Body composition to define prognosis of cancers treated by anti-angiogenic drugs","volume":"13","author":"Decazes","year":"2023","journal-title":"Diagnostics (Basel)"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103965_bib23","article-title":"Synergic prognostic value of 3D CT scan subcutaneous fat and muscle masses for immunotherapy-treated cancer","volume":"11","author":"Decazes","year":"2023","journal-title":"J\u00a0Immunother Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103965_bib24","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0009-9236(97)90166-1","article-title":"Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions","volume":"61","author":"Sotaniemi","year":"1997","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103965_bib25","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jhep.2021.08.030","article-title":"An elevated FIB-4 score predicts liver cancer development: a longitudinal analysis from 29,999 patients with NAFLD","volume":"76","author":"Loosen","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103965_bib26","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1681\/ASN.2016020154","article-title":"The substantial loss of nephrons in healthy human kidneys with aging","volume":"28","author":"Denic","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103965_bib27","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S1470-2045(19)30145-7","article-title":"Dose recommendations for anticancer drugs in patients with renal or hepatic impairment","volume":"20","author":"Krens","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103965_bib28","first-page":"CR209","article-title":"Incidence of renal insufficiency in cancer patients and evaluation of information available on the use of anticancer drugs in renally impaired patients","volume":"10","author":"Launay-Vacher","year":"2004","journal-title":"Med Sci Monit"},{"issue":"7","key":"10.1016\/j.esmoop.2024.103965_bib29","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1001\/jamasurg.2021.1438","article-title":"Survival after breast conservation vs mastectomy adjusted for comorbidity and socioeconomic status","volume":"156","author":"de Boniface","year":"2021","journal-title":"JAMA Surg"},{"issue":"11","key":"10.1016\/j.esmoop.2024.103965_bib30","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.3390\/cancers14112671","article-title":"The French early breast cancer cohort (FRESH): a resource for breast cancer research and evaluations of oncology practices based on the French National Healthcare System Database (SNDS)","volume":"14","author":"Dumas","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103965_bib31","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.50963","article-title":"Cumulative update of a systematic overview evaluating interventions addressing polypharmacy","volume":"7","author":"Keller","year":"2024","journal-title":"JAMA Network Open"},{"issue":"7","key":"10.1016\/j.esmoop.2024.103965_bib32","doi-asserted-by":"crossref","first-page":"e580","DOI":"10.1093\/oncolo\/oyac053","article-title":"Polypharmacy, potentially inappropriate medications, and drug-drug interactions in vulnerable older adults with advanced cancer initiating cancer treatment","volume":"27","author":"Ramsdale","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2024.103965_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103342","article-title":"Potential cytochrome P450-mediated pharmacokinetic interactions between herbs, food, and dietary supplements and cancer treatments","volume":"166","author":"Gougis","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"10.1016\/j.esmoop.2024.103965_bib35","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1001\/jamaoncol.2023.3329","article-title":"Geriatric assessments in older adults with cancer","volume":"9","author":"Diaz","year":"2023","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103965_bib36","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jgo.2013.04.002","article-title":"Improved targeting of cancer care for older patients: a systematic review of the utility of comprehensive geriatric assessment","volume":"4","author":"Ramjaun","year":"2013","journal-title":"J\u00a0Geriatr Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103965_bib37","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1634\/theoncologist.2019-0241","article-title":"Predicting chemotherapy toxicity and death in older adults with colon cancer: results of MOST study","volume":"25","author":"Retornaz","year":"2020","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103965_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-047376","article-title":"Cancer Aging Research Group (CARG) score in older adults undergoing curative intent chemotherapy: a prospective cohort study","volume":"11","author":"Ostwal","year":"2021","journal-title":"BMJ Open"},{"issue":"13","key":"10.1016\/j.esmoop.2024.103965_bib39","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1002\/cncr.26646","article-title":"Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score","volume":"118","author":"Extermann","year":"2012","journal-title":"Cancer"},{"issue":"25","key":"10.1016\/j.esmoop.2024.103965_bib40","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1200\/JCO.2011.34.7625","article-title":"Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study","volume":"29","author":"Hurria","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103965_bib41","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1093\/oncolo\/oyad050","article-title":"External validity of two scores for predicting the risk of chemotherapy toxicity among older patients with solid tumors: results from the ELCAPA prospective cohort","volume":"28","author":"Frelaut","year":"2023","journal-title":"Oncologist"},{"issue":"10314","key":"10.1016\/j.esmoop.2024.103965_bib42","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(21)01789-X","article-title":"Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study","volume":"398","author":"Mohile","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.esmoop.2024.103965_bib43","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.4158","article-title":"Geriatric assessment-driven intervention (GAIN) on chemotherapy-related toxic effects in older adults with cancer: a randomized clinical trial","volume":"7","author":"Li","year":"2021","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103965_bib44","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1001\/jamaoncol.2021.0848","article-title":"Efficacy of reduced-intensity chemotherapy with oxaliplatin and capecitabine on quality of life and cancer control among older and frail patients with advanced gastroesophageal cancer: the GO2 phase 3 randomized clinical trial","volume":"7","author":"Hall","year":"2021","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103965_bib45","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/s41591-023-02296-6","article-title":"Heterogeneous aging across multiple organ systems and prediction of chronic disease and mortality","volume":"29","author":"Tian","year":"2023","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.esmoop.2024.103965_bib46","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1111\/bcp.14094","article-title":"Prescribing medicines to older people\u2014how to consider the impact of ageing on human organ and body functions","volume":"86","author":"Drenth-van Maanen","year":"2020","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103965_bib47","first-page":"6","article-title":"Body composition in elderly people. I. Determination of body composition by multiisotope method and the elimination kinetics of these isotopes in healthy elderly subjects","volume":"31","author":"F\u00fcl\u00f6p","year":"1985","journal-title":"Gerontology"},{"issue":"1-2","key":"10.1016\/j.esmoop.2024.103965_bib48","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0047-6374(92)90106-N","article-title":"Hepatic cytochrome P-4503A (CYP3A) activity in the elderly","volume":"64","author":"Hunt","year":"1992","journal-title":"Mech Ageing Dev"},{"key":"10.1016\/j.esmoop.2024.103965_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.1063721","article-title":"Health-related heterogeneity in brain aging and associations with longitudinal change in cognitive function","volume":"14","author":"Wrigglesworth","year":"2023","journal-title":"Front Aging Neurosci"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103965_bib50","doi-asserted-by":"crossref","first-page":"188","DOI":"10.31083\/j.rcm2306188","article-title":"Risk factors and cardiovascular disease in the elderly","volume":"23","author":"D\u00edez-Villanueva","year":"2022","journal-title":"Rev Cardiovasc Med"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103965_bib51","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1055\/s-0042-1751234","article-title":"Epidemiology, pathophysiology, and management of coronary artery disease in the elderly","volume":"31","author":"Fadah","year":"2022","journal-title":"Int J Angiol"},{"issue":"10","key":"10.1016\/j.esmoop.2024.103965_bib52","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1093\/eurjpc\/zwac033","article-title":"Cardiovascular disease in the elderly: proceedings of the European Society of Cardiology\u2014Cardiovascular Round Table","volume":"29","author":"Lettino","year":"2022","journal-title":"Eur J Prev Cardiol"},{"issue":"41","key":"10.1016\/j.esmoop.2024.103965_bib53","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"issue":"38","key":"10.1016\/j.esmoop.2024.103965_bib54","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1093\/eurheartj\/ehab362","article-title":"Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study","volume":"42","author":"Salem","year":"2021","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103965_bib55","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/annonc\/mdh344","article-title":"Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials","volume":"15","author":"Folprecht","year":"2004","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103965_bib56","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejca.2006.11.004","article-title":"International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency","volume":"43","author":"Lichtman","year":"2007","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103965_bib57","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/annonc\/mds431","article-title":"Safety and activity of sunitinib in elderly patients (\u2265 70 years) with metastatic renal cell carcinoma: a multicenter study","volume":"24","author":"Brunello","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2024.103965_bib58","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1200\/JCO.2023.41.6_suppl.647","article-title":"Cabozantinib in the elderly with metastatic renal cell carcinoma undergoing geriatric G8 screening test: a prospective multicenter observational study (ZEBRA\/MEET-URO 9)","volume":"41","author":"Basso","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103965_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102062","article-title":"Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: implications for patient care","volume":"89","author":"Castellano","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103965_bib60","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/bjc.2013.832","article-title":"Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma","volume":"110","author":"Hutson","year":"2014","journal-title":"Br J Cancer"},{"issue":"33","key":"10.1016\/j.esmoop.2024.103965_bib61","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1200\/JCO.2013.48.7884","article-title":"Trastuzumab-related cardiotoxicity among older patients with breast cancer","volume":"31","author":"Chavez-MacGregor","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103965_bib62","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jgo.2015.06.003","article-title":"Trastuzumab in the treatment of elderly patients with early breast cancer: results from an observational study in Germany","volume":"6","author":"Dall","year":"2015","journal-title":"J\u00a0Geriatr Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103965_bib63","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.4103\/jfmpc.jfmpc_1302_20","article-title":"A\u00a0study of medication compliance in geriatric patients with chronic illness","volume":"10","author":"Punnapurath","year":"2021","journal-title":"J\u00a0Family Med Prim Care"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103965_bib64","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12877-023-03768-7","article-title":"Risk factors for self-reported medication adherence in community-dwelling older patients with multimorbidity and polypharmacy: a multicenter cross-sectional study","volume":"23","author":"Liu","year":"2023","journal-title":"BMC Geriatrics"},{"key":"10.1016\/j.esmoop.2024.103965_bib65","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ctrv.2017.05.002","article-title":"Adherence to oral cancer therapy in older adults: the International Society of Geriatric Oncology (SIOG) taskforce recommendations","volume":"57","author":"Mislang","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103965_bib66","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/ggi.14170","article-title":"Effect of clinical pharmacists\u2019 interventions on dementia treatment adherence and caregivers\u2019 knowledge","volume":"21","author":"Balli","year":"2021","journal-title":"Geriatr Gerontol Int"},{"key":"10.1016\/j.esmoop.2024.103965_bib67","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejca.2018.03.030","article-title":"Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab\u00a0+ chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer","volume":"97","author":"Aparicio","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2024.103965_bib68","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2021.01.051","article-title":"Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: a subgroup\u00a0analysis from the TOSCA trial","volume":"148","author":"Rosati","year":"2021","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.esmoop.2024.103965_bib69","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S1470-2045(20)30741-5","article-title":"Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG)","volume":"22","author":"Biganzoli","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2024.103965_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114181","article-title":"Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trials","volume":"207","author":"Nicol\u00f2","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2024.103965_bib71","doi-asserted-by":"crossref","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia: ESMO Clinical Practice Guidelines","volume":"27","author":"Klastersky","year":"2016","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103965_bib72","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1200\/JCO.2005.03.082","article-title":"Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly","volume":"23","author":"ten Tije","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103965_bib73","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1146\/annurev-pharmtox-022820-093805","article-title":"Clinical pharmacology and interplay of immune checkpoint agents: a yin-yang balance","volume":"61","author":"Geraud","year":"2021","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"10","key":"10.1016\/j.esmoop.2024.103965_bib74","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1634\/theoncologist.2017-0167","article-title":"Fixed dosing of monoclonal antibodies in oncology","volume":"22","author":"Hendrikx","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2024.103965_bib75","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.critrevonc.2017.08.010","article-title":"Clinical pharmacology of anti-angiogenic drugs in oncology","volume":"119","author":"Gougis","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"issue":"23","key":"10.1016\/j.esmoop.2024.103965_bib76","first-page":"7108","article-title":"An update on the role of anti-EGFR in the treatment of older patients with metastatic colorectal cancer","volume":"11","author":"Rosati","year":"2022","journal-title":"J\u00a0Clin Med"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103965_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2020.100042","article-title":"A\u00a0prospective cohort study on the safety of checkpoint inhibitors in older cancer patients - the ELDERS study","volume":"6","author":"Gomes","year":"2021","journal-title":"ESMO Open"},{"issue":"11","key":"10.1016\/j.esmoop.2024.103965_bib78","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1001\/jamaoncol.2019.3113","article-title":"Factors associated with immune checkpoint inhibitor\u2013related myocarditis","volume":"5","author":"Zamami","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2024.103965_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102536","article-title":"Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade\u2014a worldwide perspective","volume":"70","author":"Gougis","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103965_bib80","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/s41591-023-02771-0","article-title":"Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis","volume":"30","author":"Fenioux","year":"2024","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103965_bib81","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1200\/JCO.22.01503","article-title":"Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer in CheckMate 227","volume":"41","author":"Brahmer","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"10.1016\/j.esmoop.2024.103965_bib82","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.esmoop.2024.103965_bib83","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103965_bib84","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.esmoop.2024.103965_bib85","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.esmoop.2024.103965_bib86","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2024.103965_bib87","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1200\/JCO.2023.41.16_suppl.1006","article-title":"An age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03","volume":"41","author":"Krop","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"10411","key":"10.1016\/j.esmoop.2024.103965_bib88","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.esmoop.2024.103965_bib89","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103965_bib90","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.annonc.2024.01.002","article-title":"TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes","volume":"35","author":"Loriot","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103965_bib91","first-page":"1","article-title":"Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"10","author":"Hurvitz","year":"2024","journal-title":"NPJ Breast Cancer"},{"issue":"25","key":"10.1016\/j.esmoop.2024.103965_bib92","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.22.02887","article-title":"Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer","volume":"41","author":"O\u2019Donnell","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103965_bib93","article-title":"Antibody drug conjugates in older patients: state of the art","volume":"193","author":"Rached","year":"2024","journal-title":"Criti Rev Oncol Hematol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103965_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102029","article-title":"Bridging the gap: addressing disparities of access to oncology clinical trials in the geriatric population","volume":"8","author":"Rached","year":"2023","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103965_bib95","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.jgo.2020.09.020","article-title":"Incidence and prognostic factors of clinically meaningful toxicities of kinase inhibitors in older patients with cancer: the PreToxE study","volume":"12","author":"Lebreton","year":"2021","journal-title":"J\u00a0Geriatr Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103965_bib96","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10549-020-06029-y","article-title":"Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials","volume":"186","author":"Goetz","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2024.103965_bib97","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1200\/JCO.2021.39.15_suppl.1012","article-title":"PALOMAGE, a French real-world cohort of elderly women beyond age 70 with advanced breast cancer receiving palbociclib: baseline characteristics and safety evaluation","volume":"39","author":"Caillet","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103965_bib98","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/cpt.1950","article-title":"Ribociclib drug-drug interactions: clinical evaluations and physiologically-based pharmacokinetic modeling to guide drug labeling","volume":"108","author":"Samant","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.esmoop.2024.103965_bib100","first-page":"47","article-title":"Rhabdomyolysis induced by the interaction between ribociclib and statins- case report and literature review","volume":"15","author":"Badran","year":"2023","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103965_bib101","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.esmoop.2024.103965_bib102","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.esmoop.2024.103965_bib103","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1056\/NEJMra1307118","article-title":"Systemic therapy for estrogen receptor\u2013positive, HER2-negative breast cancer","volume":"383","author":"Burstein","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103965_bib104","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1634\/theoncologist.7-6-477","article-title":"FDA drug approval summaries: fulvestrant","volume":"7","author":"Bross","year":"2002","journal-title":"Oncologist"},{"issue":"28","key":"10.1016\/j.esmoop.2024.103965_bib105","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","article-title":"Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven","volume":"26","author":"Attard","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2024.103965_bib106","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s40262-015-0271-5","article-title":"Clinical pharmacokinetic studies of enzalutamide","volume":"54","author":"Gibbons","year":"2015","journal-title":"Clin Pharmacokinet"},{"issue":"7-8","key":"10.1016\/j.esmoop.2024.103965_bib107","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.bulcan.2023.01.018","article-title":"Management of cancer treatments in hemodialysis patients","volume":"111","author":"Matte","year":"2024","journal-title":"Bull Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103965_bib108","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s11523-019-00674-0","article-title":"Evaluation of clinically relevant drug\u2013drug interactions and population pharmacokinetics of darolutamide in patients with nonmetastatic castration-resistant prostate cancer: results of pre-specified and post hoc analyses of the phase III ARAMIS trial","volume":"14","author":"Shore","year":"2019","journal-title":"Target Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103965_bib109","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2024.103965_bib110","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11886-021-01561-9","article-title":"Cardiovascular toxicity of androgen deprivation therapy","volume":"23","author":"Boland","year":"2021","journal-title":"Curr Cardiol Rep"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103965_bib111","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jaccao.2023.05.011","article-title":"Cardiovascular effects of GnRH antagonists compared with agonists in prostate cancer: a systematic review","volume":"5","author":"Nelson","year":"2023","journal-title":"JACC CardioOncol"},{"issue":"11","key":"10.1016\/j.esmoop.2024.103965_bib112","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/S0959-8049(98)00207-X","article-title":"Carboplatin-oral etoposide personalized dosing in elderly non-small cell lung cancer patients. Gruppo Oncologico Cooperativo Sud-Italia","volume":"34","author":"Frasci","year":"1998","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103965_bib113","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2016-000091","article-title":"Renal insufficiency and cancer treatments","volume":"1","author":"Launay-Vacher","year":"2016","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.esmoop.2024.103965_bib114","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/annonc\/mdm011","article-title":"Renal insufficiency in elderly cancer patients: international Society of Geriatric Oncology clinical practice recommendations","volume":"18","author":"Launay-Vacher","year":"2007","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.esmoop.2024.103965_bib115","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.3748\/wjg.v25.i15.1817","article-title":"Considerations of elderly factors to manage the complication of liver cirrhosis in elderly patients","volume":"25","author":"Kamimura","year":"2019","journal-title":"World J Gastroenterol"},{"issue":"14","key":"10.1016\/j.esmoop.2024.103965_bib116","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1200\/JCO.2007.10.6583","article-title":"International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients--an analysis of the medical literature","volume":"25","author":"Lichtman","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103965_bib117","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12885-019-6472-9","article-title":"Comorbidity prevalence among cancer patients: a population-based cohort study of four cancers","volume":"20","author":"Fowler","year":"2020","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103965_bib118","doi-asserted-by":"crossref","DOI":"10.2196\/26425","article-title":"Physical comorbidities and their relationship with cancer treatment and its outcomes in older adult populations: systematic review","volume":"7","author":"George","year":"2021","journal-title":"JMIR Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103965_bib119","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jgo.2015.12.002","article-title":"Comorbidity in older adults with cancer","volume":"7","author":"Williams","year":"2016","journal-title":"J\u00a0Geriatr Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2024.103965_bib120","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1002\/ijc.33119","article-title":"Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors","volume":"147","author":"Abu Rmilah","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.esmoop.2024.103965_bib121","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ctrv.2017.11.009","article-title":"Management of QT prolongation induced by anti-cancer drugs: target therapy and old agents. Different algorithms for different drugs","volume":"63","author":"Coppola","year":"2018","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103965_bib122","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/1078155217748735","article-title":"Approach to initiating QT-prolonging oncology drugs in the ambulatory setting","volume":"25","author":"de Lemos","year":"2019","journal-title":"J\u00a0Oncol Pharm Pract"},{"key":"10.1016\/j.esmoop.2024.103965_bib123","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.613625","article-title":"QT prolongation in cancer patients","volume":"8","author":"Kim","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103965_bib124","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s40801-021-00234-x","article-title":"Drug-associated QTc prolongation in geriatric hospitalized patients: a cross-sectional study in internal medicine","volume":"8","author":"Rossi","year":"2021","journal-title":"Drugs Real World Outcomes"},{"issue":"19","key":"10.1016\/j.esmoop.2024.103965_bib125","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1200\/JCO.2007.14.1242","article-title":"Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin\u2019s lymphoma","volume":"26","author":"Hershman","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2024.103965_bib126","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103965_bib127","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jgo.2019.05.008","article-title":"Subgroup analysis of older patients treated within the randomized phase 3 doxorubicin versus doxorubicin plus evofosfamide (SARC021) trial","volume":"11","author":"Younger","year":"2020","journal-title":"J\u00a0Geriatr Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103965_bib128","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00280-019-03775-9","article-title":"Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP","volume":"83","author":"Baudry","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103965_bib129","first-page":"953","article-title":"Biweekly docetaxel is better tolerated than conventional three-weekly dosing for advanced hormone-refractory prostate cancer","volume":"32","author":"Hervonen","year":"2012","journal-title":"Anticancer Res"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103965_bib130","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.eururo.2008.07.078","article-title":"Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer","volume":"55","author":"Italiano","year":"2009","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103965_bib131","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.ejca.2014.01.006","article-title":"Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme","volume":"50","author":"Heidenreich","year":"2014","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.esmoop.2024.103965_bib132","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1001\/jamaoncol.2023.4255","article-title":"Biweekly vs triweekly cabazitaxel in older patients with metastatic castration-resistant prostate cancer: the CABASTY phase 3 randomized clinical trial","volume":"9","author":"Oudard","year":"2023","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103965_bib133","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3816\/CLC.2008.n.043","article-title":"Weekly paclitaxel in elderly patients (aged > or\u00a0= 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study","volume":"9","author":"Rossi","year":"2008","journal-title":"Clin Lung Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103965_bib134","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/BF00689192","article-title":"The influence of ageing on cisplatin pharmacokinetics in lung cancer patients with normal organ function","volume":"36","author":"Yamamoto","year":"1995","journal-title":"Cancer Chemother Pharmacol"},{"issue":"25","key":"10.1016\/j.esmoop.2024.103965_bib135","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1200\/JCO.2006.06.9039","article-title":"Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil\/leucovorin administered bimonthly in elderly patients with colorectal cancer","volume":"24","author":"Goldberg","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103965_bib136","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/annonc\/mdf089","article-title":"First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil\/leucovorin","volume":"13","author":"Cassidy","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2024.103965_bib137","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejca.2017.05.044","article-title":"Immune checkpoint inhibitors and elderly people: a review","volume":"82","author":"Daste","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2024.103965_bib138","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1200\/EDBK_201435","article-title":"Immunotherapy in older adults with advanced cancers: implications for clinical decision-making and future research","volume":"38","author":"Kanesvaran","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103965_bib139","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1756-9966-33-30","article-title":"Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme","volume":"33","author":"Chiarion Sileni","year":"2014","journal-title":"J\u00a0Exp Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2024.103965_bib140","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1020058","article-title":"Efficacy and toxicity of ipilimumab-nivolumab combination therapy in elderly metastatic melanoma patients","volume":"12","author":"Stoff","year":"2022","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103965_bib141","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/bjc.2011.554","article-title":"Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer","volume":"106","author":"Jehn","year":"2012","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103965_bib142","first-page":"118","article-title":"Benefit of rituximab maintenance is associated with Follicular Lymphoma International Prognostic Index in patients with follicular lymphoma","volume":"5","author":"Li","year":"2023","journal-title":"Blood Sci"},{"issue":"14","key":"10.1016\/j.esmoop.2024.103965_bib143","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2011-09-380949","article-title":"The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL","volume":"119","author":"M\u00fcller","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103965_bib144","doi-asserted-by":"crossref","first-page":"869","DOI":"10.4103\/jcrt.JCRT_833_17","article-title":"Efficacy and safety of bevacizumab in elderly patients with advanced colorectal cancer: a meta-analysis","volume":"13","author":"Chen","year":"2017","journal-title":"J\u00a0Cancer Res Ther"},{"key":"10.1016\/j.esmoop.2024.103965_bib145","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2147\/CIA.S54675","article-title":"Bevacizumab treatment in the elderly patient with metastatic colorectal cancer","volume":"10","author":"Di Bartolomeo","year":"2015","journal-title":"Clin Interv Aging"},{"issue":"28","key":"10.1016\/j.esmoop.2024.103965_bib146","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1200\/JCO.2012.48.4857","article-title":"Contraindicated use of bevacizumab and toxicity in elderly patients with cancer","volume":"31","author":"Hershman","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103965_bib147","doi-asserted-by":"crossref","first-page":"5231","DOI":"10.21873\/anticanres.12847","article-title":"Efficacy and safety data of osimertinib in elderly patients with NSCLC who harbor the EGFR T790M mutation after failure of initial EGFR-TKI treatment","volume":"38","author":"Furuta","year":"2018","journal-title":"Anticancer Res"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103965_bib148","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.3390\/pharmaceutics14091844","article-title":"Exposure-response analysis of osimertinib in patients with advanced non-small-cell lung cancer","volume":"14","author":"Rodier","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103965_bib149","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-02561-z","article-title":"First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002)","volume":"11","author":"Yamamoto","year":"2021","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.esmoop.2024.103965_bib150","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1080\/17425255.2016.1239717","article-title":"Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses","volume":"12","author":"Bose","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103965_bib151","first-page":"273","article-title":"Efficacy and safety of ibrutinib therapy in patients with chronic lymphocytic leukemia: retrospective analysis of real-life data","volume":"38","author":"Tombak","year":"2021","journal-title":"Turk J Haematol"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2024.103965_bib152","doi-asserted-by":"crossref","first-page":"e15061","DOI":"10.1200\/JCO.2021.39.15_suppl.e15061","article-title":"Cardiovascular toxicities associated with ibrutinib in elderly patients","volume":"39","author":"Yudiono","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"48","key":"10.1016\/j.esmoop.2024.103965_bib153","doi-asserted-by":"crossref","first-page":"80083","DOI":"10.18632\/oncotarget.11657","article-title":"Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome","volume":"7","author":"Iurlo","year":"2016","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.esmoop.2024.103965_bib154","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s40266-013-0088-6","article-title":"Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study","volume":"30","author":"Latagliata","year":"2013","journal-title":"Drugs Aging"},{"key":"10.1016\/j.esmoop.2024.103965_bib155","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1182\/blood.V118.21.2770.2770","article-title":"Imatinib in very elderly (> 75 years) CML patients: are low-doses","volume":"118","author":"Latagliata","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.esmoop.2024.103965_bib156","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s40262-022-01167-6","article-title":"Pharmacokinetics and pharmacodynamics of PARP inhibitors in oncology","volume":"61","author":"Bruin","year":"2022","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"10.1016\/j.esmoop.2024.103965_bib157","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1136\/ijgc-2022-003614","article-title":"Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis","volume":"32","author":"Maiorano","year":"2022","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103965_bib158","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/S2352-3026(20)30360-4","article-title":"Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database","volume":"8","author":"Morice","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.esmoop.2024.103965_bib159","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejca.2022.11.029","article-title":"Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged \u226565 years from the PAOLA-1\/ENGOT-ov25 trial","volume":"181","author":"Sabatier","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2024.103965_bib160","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918809610","article-title":"Use of cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitors in older patients with ER-positive HER2-negative breast cancer: Young International Society of Geriatric Oncology review paper","volume":"10","author":"Battisti","year":"2018","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103965_bib161","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/10781552211050106","article-title":"A\u00a0deep dive into CDK4\/6 inhibitors: evaluating real world toxicities and treatment paradigms in the elderly population","volume":"29","author":"Olazagasti","year":"2023","journal-title":"J\u00a0Oncol Pharm Pract"},{"key":"10.1016\/j.esmoop.2024.103965_bib162","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.breast.2023.03.015","article-title":"Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer","volume":"69","author":"Rugo","year":"2023","journal-title":"Breast"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103965_bib163","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s12094-021-02766-8","article-title":"Expert consensus to optimize the treatment of elderly patients with luminal metastatic breast cancer","volume":"24","author":"Torregrosa-Maicas","year":"2022","journal-title":"Clin Transl Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103965_bib164","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1517\/17425255.2015.1041918","article-title":"Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer","volume":"11","author":"Han","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103965_bib165","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.clgc.2015.07.019","article-title":"Safety and clinical outcomes of abiraterone acetate after docetaxel in octogenarians with metastatic castration-resistant prostate cancer: results of the Italian compassionate use named patient programme","volume":"14","author":"Maines","year":"2016","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103965_bib166","first-page":"1277","article-title":"Efficacy and safety of abiraterone acetate in elderly (75 years or older) chemotherapy na\u00efve patients with metastatic castration resistant prostate cancer","volume":"194","author":"Smith","year":"2015","journal-title":"J\u00a0Urol"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103965_bib167","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s10637-011-9764-8","article-title":"Sorafenib exposure decreases over time in patients with hepatocellular carcinoma","volume":"30","author":"Arrondeau","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.esmoop.2024.103965_bib168","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113258","article-title":"Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trial","volume":"192","author":"Fizazi","year":"2023","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103965_bib169","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/annonc\/mdv542","article-title":"Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL","volume":"27","author":"Graff","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2024.103965_bib170","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221149887","article-title":"Androgen receptor pathway inhibitors, prostate cancer, and older adults: a global Young International Society of Geriatric Oncology drug review","volume":"15","author":"Mir","year":"2023","journal-title":"Ther Adv Med Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103965_bib171","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s13318-019-00577-5","article-title":"Drug-drug interaction potential of darolutamide: in\u00a0vitro and clinical studies","volume":"44","author":"Zurth","year":"2019","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.esmoop.2024.103965_bib172","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4137\/CMO.S26067","article-title":"Treating elderly patients with hormone receptor-positive advanced breast cancer","volume":"9","author":"Riseberg","year":"2015","journal-title":"Clin Med Insights Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103965_bib173","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1517\/17425255.2015.1037277","article-title":"Effect of age on drug metabolism in women with breast cancer","volume":"11","author":"Singh","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924017356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924017356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T21:14:52Z","timestamp":1733778892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924017356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":170,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2059702924017356"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103965","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of solid oncology drugs in older patients: a narrative review","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103965","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"103965"}}